ReviewHealth services insights2026
The Economic Costs of Congenital Hearing Loss in a South African Cohort.
Review in Health services insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of congenital hearing loss in South Africa is estimated to be 6 per 1000 live births, which is higher than most high-income countries but consistent with rates observed in other parts of Africa. While policymakers typically focus on direct healthcare-related costs, many of the broader societal and economic impacts of congenital hearing loss remain hidden, including educational, vocational, and social consequences. Understanding the full economic burden is essential for informed policy and healthcare planning. Objectives: To assess the full economic burden of congenital hearing loss, including indirect and intangible costs in South Africa. Design: A cost-of-illness model from a societal perspective in 2022. Methods: We constructed a cohort-survival model to estimate the societal lifetime costs of congenital hearing loss. Cost components included direct medical expenses (diagnostics, devices, surgeries), non-medical costs (special education), indirect costs (lost productivity, reduced earnings) and the monetary value of disability adjusted life years lost due to hearing loss. Model inputs were derived from published literature and consultation with experts. Results: Total economic cost for the cohort was ZAR 16.4 billion (USD 1 billion per lifetime or ZAR 256 million (USD 15.9 million) per year. Productivity losses made up the largest proportion of societal costs with losses of approximately ZAR 2.4 billion (52% of total costs). Total discounted cost per person with hearing loss was ZAR 1.1 million (USD 70 thousand) per lifetime. Conclusion: Congenital hearing loss has far-reaching implications beyond immediate healthcare expenses, including significant societal and economic costs. Early childhood interventions such as newborn screening and early identification, assistive devices and speech and language therapy interventions may reduce the high costs associated with congenital hearing loss and may provide substantial returns on investment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.